BioCardia, Inc.

BCDA

US09060U5074

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 11/05/2024 am IST			5-day change	1st Jan Change
0.3959 ^USD	-1.02%		+4.21%	-40.39%

01/05	BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial	CI
30/04	Transcript : BioCardia, Inc. - Special Call

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

April 25, 2024 at 06:30 pm IST

BioCardia, Inc. announced completion of enrollment and collection of the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial.

Latest news about BioCardia, Inc.

BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial	01/05	CI
Transcript : BioCardia, Inc. - Special Call	01/05
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	25/04	CI
Transcript : BioCardia, Inc., 2023 Earnings Call, Mar 27, 2024	28/03
BioCardia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
BioCardia, Inc. and StemCardia, Inc. Announce Long-Term Partnership to Advance StemCardia?s Investigational Pluripotent Stem Cell Product Candidate for Treatment of Heart Failure	13/03	CI
BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	12/03	CI
Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	04/03	CI
BioCardia, Inc. announced that it expects to receive $0.874999 million in funding	09/02	CI
BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	08/02	CI
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction	19/12	CI
BioCardia, Inc. Announces Expected Cardiamp Heart Failure Japan Approval Based on Pharmaceutical and Medical Device Agency Consultation Minutes	18/12	CI
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure	29/11	CI
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon	17/11	MT
Sector Update: Health Care	17/11	MT
BioCardia to Sell $1.3 Million Shares to Healthcare Investor; Shares Fall	17/11	MT
Sector Update: Health Care Stocks Higher Late Afternoon	15/11	MT
Top Midday Gainers	15/11	MT
Sector Update: Health Care Stocks Advancing in Afternoon Trading	15/11	MT
Sector Update: Health Care	15/11	MT
BioCardia Climbs Amid FDA Approval for Phase 3 Trial of CardiAMP Cell Therapy for Ischemic Heart Failure	14/11	MT
BioCardia Shares Double After FDA Approves CardiAMP Trial	14/11	DJ
BioCardia, Inc. Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure	14/11	CI
Transcript : BioCardia, Inc., Q3 2023 Earnings Call, Nov 08, 2023	09/11
Earnings Flash (BCDA) BIOCARDIA Posts Q3 Revenue $357,000	09/11	MT

BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform.

Sector

Biotechnology & Medical Research

Calendar

14/05/2024 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for BioCardia, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.3959 USD

Average target price

4 USD

Spread / Average Target

+910.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOCARDIA, INC.	-40.39%	10.64M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs

BioCardia, Inc.

Equities

BCDA

US09060U5074

Biotechnology & Medical Research

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

Latest news about BioCardia, Inc.

Chart BioCardia, Inc.

Company Profile

Income Statement Evolution

Ratings for BioCardia, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs